Stem Cell Clinic Expansion Of Products Articles & Analysis
37 news found
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. In 2017, the Food and Drug Administration (FDA) took significant steps towards regulating stem cell therapy, marking a pivotal ...
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing product. The results ...
IPL stands for Intense Pulse Light, light emitted is absorbed by the hair pigment and changed into heat to damage the targeted hair follicle. IPL technology is not suitable for treating sensitive and/or darker skin types. SHR stands for Super Hair Removal, the latest pain free advancement in Laser/IPL permanent hair removal systems. With SHR technology, only 50 per cent of the energy targets the ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) is pleased to announce the appointment of Mr. Peter Pavlin, P.Eng. to the position of Vice President Operations. Mr. Pavlin earned his Bachelor of Applied Science and Master of Engineering degrees in Mechanical Engineering from the University of Toronto, Canada’s top ranked ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) is pleased to announce Mr. Richard (“Rick”) Groome has joined Hemostemix as a special advisor to the CEO, focused on completing a series of financing transactions. Over the last three decades Mr. Groome was instrumental in creating and building two securities firms, Marleau ...
ARLINGTON, Mass., May 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported clinical data from a Phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven ...
TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the launch of The Stem Cell SpaceShot Grant, a $100,000 research funding in the field of stem cell biology and regenerative medicine. The Stem Cell Spaceshot Grant is open to PhD-level scientists and PhD ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) Calgary, Alberta — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) is pleased to announce that it has entered into a settlement agreement (the “Settlement Agreement”) with Aspire Health Science, LLC ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions has appointed Mark Borman as Chairman of the Board as Dr. William P. Murphy Jr transitions to Chairman Emeritus. “Mark Borman brings the best of both small-enterprise experience and large-company discipline.. In addition to the valuable ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) announces that it has closed its previously announced non-brokered private placement of units (“Units”) announced on February 2, 2022, for gross proceeds of $1,204,849.92 (the “Offering”). The Offering consisted of the issuance of an aggregate of 8,606,071 Units at a price of ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce it has signed a Global Master Services Agreement with My Next Health (“MNH”), and has, subject to TSXV approval, obtained a subscription from My Next Health in the amount of USD $150,000 at CAD $0.25 per Unit. My Next Health Inc. (“MNH”) is the ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce it has signed a contract with Dr. James Shapiro, University of Alberta, Edmonton and will complete a transfer ACP-01 to Dr. Shapiro’s laboratory. The combination of ACP-01, an autologous angiogenic cell precursor that has demonstrated improvement of angiogenesis ...
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders, today announced three promotions within its leadership team: Catherine Priest, Ph.D., previously Neurona’s vice president of preclinical development, has been appointed to chief development officer, Gautam Banik, Ph.D., formerly Neurona’s ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce the source document verification process has been completed and the Company has soft locked the HS 12-01 database. Next, each of the principal investigators will sign off the source documentation of the subjects they followed. Following the sign off by all principal ...
U.S. Stem Cell’s longstanding animal division, Vetbiologics, has for years provided the Veterinary field with comprehensive regenerative medicine solutions – from training to products and services. ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTC: HMTXF; FRA:2VFO) is pleased to announce the appointment of Dr. Fraser C. Henderson Sr., MD, as its Chief Medical Officer. Dr. Fraser C. Henderson Sr. is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science. Dr. Henderson is ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce the second in its series of video interviews with ACP-01 recipients taped during August of 2021. With more than 300 patients treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, vascular dementia, COPD, and pulmonary hypertension, in this ...
First use of a nanotechnology enhanced pedicle screw with label claims to increase and accelerate human osteoblast and mesenchymal stem cell calcified extracellular matrix production in vitro CARMEL, Ind., Sept. 28, 2021 - Nanovis, an award winning technology company with unique and differentiated nanotechnology surfaces for improving bone growth and fighting infection, is pleased to announce ...
ByNanovis
SUNRISE, FL – June. 8th, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a corporation that has historically focused on the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products in both human and veterinary stem cell processes , has received the results of the Appeal from the United States 11th District Court for the ...
Today, French cell therapy company TreeFrog Therapeutics released data showing the mass production of human induced pluripotent stem cells (hiPSC) produced with their proprietary C-Stem™ technology in 10L bioreactors at the 2021 Annual Meeting of the International Society for Stem ...